Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Crohn's Disease Treatment Market size was over USD 14.05 billion in 2024 and is anticipated to cross USD 23.99 billion by 2037, growing at more than 4.2% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of crohn's disease treatment is estimated at USD 14.55 billion.
Increasing incidence of bowel disorders such as Crohn's disease due to lifestyle changes, rising awareness about Crohn's disease and the availability of treatments is expected to fuel this market progress. The growth of the market can also be attributed to the rising prevalence of Crohn’s disease amongst individuals on a global level.
Crohn's Disease Treatment Sector: Growth Drivers and Challenges
Growth Drivers
- Increasing Incidence of Crohn’s Disease Due to Lifestyle Changes
- Increasing Awareness About Crohn’s Disease, and the Availability of Treatments
Challenges
- High Cost of Treatment
- Delay In Diagnosis and Lack of Awareness
Crohn's Disease Treatment Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
4.2% |
|
Base Year Market Size (2024) |
USD 14.05 billion |
|
Forecast Year Market Size (2037) |
USD 23.99 billion |
|
Regional Scope |
|
Crohn's Disease Treatment Segmentation
On the basis of type, the crohn's disease treatment market is segmented into Ileocolitis, Ileitis, Granulomatous colitis, Gastroduodenal Crohn's Disease, Jejunoileitis, and Perianal Crohn’s Disease. Out of which, the Ileocolitis segment is anticipated to garner largest share as this is the most common type of Crohn's disease. It causes inflammation of the lower portion of the small intestine, or ileum, and the large intestine, or colon.
On the basis of treatment, the market is segmented into surgical and non-surgical. Out of these two, non-surgical holds the highest share, over the forecast period. Non-surgical is further divided into anti-inflammatory, immune system suppressors, antibiotics, and others. In 2020, the anti-inflammatory segment was the largest segment of the market due to its greater efficacy compared to analgesic and immunosuppressants, while the immune system suppressors segment is expected to be the fastest-growing segment due to the reduction in surgeries and hospitalization rates.
On the basis of end users, the market is segmented into hospitals and clinics, research institutes, and others. The hospitals segment is expected to hold the highest share of the market as a considerable portion of the population with Crohn’s disease on a global level tend to choose healthcare facilities specializing in its treatment.
Our in-depth analysis of the global market includes the following segments:
|
By Type |
|
|
By Treatment |
|
|
By End User |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportCrohn's Disease Treatment Industry - Regional Synopsis
Geographically, the crohn's disease treatment market is segmented into North America, Latin America, Europe, Asia Pacific, and the Middle East & Africa region. Asia Pacific industry is anticipated to account for largest revenue share by 2037, owing to increasing awareness about Crohn’s disease, and need to develop innovative inflammatory bowel disease treatment solutions in the region. Increasing R&D of biosimilars for the treatment of Crohn’s disease is expected to boost growth of the market in the Asia Pacific. In 2021, the market in North America is evaluated to occupy the largest share in terms of revenue, owing to the R&D of novel biosimilars and drugs for the Crohn’s disease treatment. For instance, in August 2016, the U.S. Food and Drug Administration (FDA) approved two biosimilars Amjevita and Erelzi, manufactured by Amgen to treat inflammatory bowel disease.
Companies Dominating the Crohn's Disease Treatment Landscape
- Johnson & Johnson Services Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Pfizer Inc.
- Allergan
- AbbVie Inc.
- Bayer AG
- Amgen Inc.
- Takeda Pharmaceutical Company Limited
- UCB S.A.
- Ferring B.V.
- Eli Lilly Company
- Hoffman-La Roche
- Bristol-Myers Squib
In the News
Author Credits: Radhika Pawar
- Report ID: 3004
- Published Date: Dec 26, 2024
- Report Format: PDF, PPT
